Literature DB >> 12731672

Induction of complete remission of hypoplastic leukemia with antithymocyte globulin.

Ayami Yoshimi1, Chikako Nakamoto, Yoichi Nakamura, Koji Kato, Takaharu Matsuyama, Kazuko Kudo, Seiji Kojima.   

Abstract

A 13-year-old boy was admitted to a local hospital because of pancytopenia. A bone marrow aspiration and biopsy revealed severely hypocellular marrow with no obvious leukemic cells. The diagnosis was severe aplastic anemia, and the patient was treated with antithymocyte globulin and cyclosporin A. A trilineage response was obtained, and the patient became transfusion-independent within 2 weeks. Two months later, the peripheral blood count normalized with an increased bone marrow cellularity. However, the patient was readmitted 5 months later for recurrence of the pancytopenia. A bone marrow aspiration revealed hypocellular marrow with morphologically blastoid cells. A surface marker study revealed the presence of a single clone that was positive for CD7, CD33, CD34, and HLA-DR. A diagnosis of hypoplastic leukemia was made on the basis of morphology and the surface marker studies. Retrospectively, the laboratory findings were the same as those seen at the onset of the disease. The patient did not respond to combination chemotherapy consisting of vincristine, prednisolone, cyclophosphamide, L-asparaginase, and doxorubicin, but administration of etoposide resulted in complete remission. An in vitro study revealed that >95% of the leukemic cells of this patient could be lysed after an incubation with antithymocyte globulin and human AB serum or baby rabbit serum. These findings suggest the efficacy of antithymocyte globulin in treating certain hypoplastic leukemias.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12731672     DOI: 10.1007/bf02983786

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  25 in total

1.  Therapy with CD7 monoclonal antibody TH-69 is highly effective for xenografted human T-cell ALL.

Authors:  W Baum; H Steininger; H J Bair; W Becker; T E Hansen-Hagge; M Kressel; E Kremmer; J R Kalden; M Gramatzki
Journal:  Br J Haematol       Date:  1996-11       Impact factor: 6.998

2.  Action of antithymocyte globulin on normal human erythroid progenitor cell proliferation in vitro: erythropoietic growth-enhancing factors are released from marrow accessory cells.

Authors:  K F Mangan; L D'Alessandro; M T Mullaney
Journal:  J Lab Clin Med       Date:  1986-04

3.  Antithymocyte globulin treatment in patients with aplastic anemia: a prospective randomized trial.

Authors:  R Champlin; W Ho; R P Gale
Journal:  N Engl J Med       Date:  1983-01-20       Impact factor: 91.245

4.  Antithymocyte globulin reacts with many normal human cell types.

Authors:  B Greco; L Bielory; D Stephany; S M Hsu; P Gascon; A Nienhuis; N Young
Journal:  Blood       Date:  1983-11       Impact factor: 22.113

5.  Effect of antilymphocyte globulin on granulocyte precursors in aplastic anaemia.

Authors:  A Faille; A J Barrett; N Balitrand; F Ketels; E Gluckman; Y Najean
Journal:  Br J Haematol       Date:  1979-07       Impact factor: 6.998

6.  Immunosuppressive therapy using antithymocyte globulin, cyclosporine, and danazol with or without human granulocyte colony-stimulating factor in children with acquired aplastic anemia.

Authors:  S Kojima; S Hibi; Y Kosaka; M Yamamoto; M Tsuchida; H Mugishima; K Sugita; H Yabe; A Ohara; I Tsukimoto
Journal:  Blood       Date:  2000-09-15       Impact factor: 22.113

7.  Induction of Fas (Apo-1, CD95)-mediated apoptosis of activated lymphocytes by polyclonal antithymocyte globulins.

Authors:  L Genestier; S Fournel; M Flacher; O Assossou; J P Revillard; N Bonnefoy-Berard
Journal:  Blood       Date:  1998-04-01       Impact factor: 22.113

8.  Complete remission in a patient with hypoplastic acute lymphoblastic leukemia induced by granulocyte-colony-stimulating factor.

Authors:  Y Hatta; T Iwata; J Takeuchi; T Ohshima; T Horie
Journal:  Acta Haematol       Date:  1995       Impact factor: 2.195

9.  Increase of erythropoiesis and thrombopoiesis, and induction of remission by granulocyte colony-stimulating factor (G-CSF) in a patient with hypoplastic leukemia.

Authors:  K Yanagisawa; A Yano; K Takada; M Yasukawa; S Fujita
Journal:  Leukemia       Date:  1994-07       Impact factor: 11.528

10.  Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma.

Authors:  D G Maloney; T M Liles; D K Czerwinski; C Waldichuk; J Rosenberg; A Grillo-Lopez; R Levy
Journal:  Blood       Date:  1994-10-15       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.